Kupando has raised an additional €10M in Series A financing, bringing its total to €23M, to fund Phase 1b trials of KUP101.

Detailed price information for Oncolytics Biotech Inc (ONCY-Q) from The Globe and Mail including charting and trades.

The finding suggests other chemo drugs, too, may be making cancer cells cause a surprising immune-system reaction.

A new discovery from researchers at The University of Texas at Austin and The University of Texas MD Anderson Cancer Center helps explain why some ...

From your digestive system to sleep, here are the overlooked signals that indicate your health could be struggling ...

CERRITOS, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- Liminatus today announced plans to initiate a Phase 1 clinical trial evaluating IBA101, a next-generation CD47-blocking monoclonal antibody ...

Researchers are redesigning lipid nanoparticles to do more than shuttle mRNA into cells, with preclinical studies suggesting ...

The dangers for infection aren’t only caused by microbes, but also by the molecular signals they release. To detect and neutralize these signals, may be the next era for infectious disease control.” — ...

Pheast Therapeutics, a clinical-stage biotechnology company advancing macrophage-directed immunotherapies for cancer, today announced that it will present three abstracts at the American Association ...

In the intricate regulation of inflammation, metabolic reprogramming and posttranslational modification (PTM) have emerged as pivotal players, offering new avenues for understanding the fine-tuned ...

The MomToker has been open online about her struggle with a chronic illness online and on 'The Secret Lives of Mormon Wives' ...